A study assessed clinical characteristics and prognosis among patients with primary bone diffuse large B-cell lymphoma (DLBCL). The findings appeared in the Journal of Experimental Hematology.
Researchers collated clinical data of 15 patients (median age, 59 years; seven men and eight women) with primary DLBCL who were treated from January 2013 to December 2020 and retrospectively assessed clinical data and prognosis of the patients.
According to the results, ostealgia was the initial symptom. The pathological types of the 15 patients were DLBCL, five cases of Has-type germinal center B-cell like (GCB) subtype, and 10 cases of non-GCB subtype, the researchers noted. From the population, 11 patients received chemotherapy, three patients received surgery, and one patient was untreated.
Overall, eight patients achieved complete remission, three achieved partial remission, one patient achieved stable disease, one patient was lost to follow-up, one patient was untreated, and one patient had progression of disease. The researchers found that neither age, pathological subtype, sex, stage, ?2-microglubin level, lactate dehydrogenase level, nor the use of rituximab were correlated with achieving complete remission (P>0.05). However, the IPI score was correlated with the recent complete remission rate (P<0.05).
“The first symptom of primary bone diffuse large B-cell lymphoma is bone pain, the main pathological subtype is non-GCB, the optimal treatment is combined chemotherapy, and the IPI score is related to the prognosis of the treatment,” the researchers concluded.
